Reed’s Faces NYSE Deficiency with $2.7M Equity, Plan Deadline
REED•Reed’s reported stockholders’ equity of $2.7 million as of March 31, 2026 and net losses over its past five fiscal years, triggering a NYSE American deficiency notice. The Company must submit a compliance restoration plan by June 28, 2026 to regain listing standards by November 29, 2027.
1. NYSE American Deficiency Notice
On May 29, 2026, Reed’s received formal notice from NYSE American that its reported $2.7 million in stockholders’ equity at March 31, 2026 fell below required standards under Sections 1003(a)(ii) and (iii), compounded by net losses in each of the last five fiscal years.
2. Required Cure Plan Submission
The Company has until June 28, 2026 to file a detailed plan outlining steps to restore compliance, with an eighteen-month cure period extending to November 29, 2027 during which its common stock will remain listed and traded, subject to other listing requirements.
3. Listing Risks and Outlook
Failure to regain compliance by the end of the cure period could result in delisting, heightening the need for strategic measures such as capital injections, cost reductions or equity raises to bolster stockholders’ equity and stabilize financial performance.
